Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 15/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981629 | 0.86 | NR1H2 (0.54) | MRGPRX4NR1H2NR1H3 | |
| SCHEMBL5389326 | 0.85 | MRGPRX4 (0.60) | MRGPRX4NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL30427926 | 0.85 | MRGPRX4 (0.72) | MRGPRX4 | |
| SCHEMBL3980539 | 0.84 | FFAR4 (0.52) | MRGPRX4NR1H2NR1H3 | |
| SCHEMBL19728976 | 0.80 | RXRA (0.71) | MRGPRX4NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL542343 | 0.79 | NR1H3 (0.52) | NR1H2NR1H3 | |
| SCHEMBL3977512 | 0.76 | LMNA (0.58) | MRGPRX4NR1H2NR1H3RAB9ASMN1; SMN2 | |
| SCHEMBL1532826 | 0.76 | NPC1 (0.61) | MRGPRX4NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL3976637 | 0.75 | MRGPRX4 (0.56) | MRGPRX4 | |
| SCHEMBL4456755 | 0.75 | MRGPRX4 (0.52) | MRGPRX4NPC1NFKB1RAB9ANFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101031540-B | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | claimed |
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | claimed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | claimed |
| CN-101031540-A | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | CN | claimed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | claimed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | claimed |
| CN-101031540-B | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | disclosed |
| CN-101031540-A | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | CN | disclosed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | NR1H3, NR1H2, NR1I2 | MRGPRX4 157/4885NR1H2 2/4885NR1H3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.